Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acellular Dermal Matrices: The New Standard In Breast Reconstruction

Executive Summary

Recent advances in breast cancer surgical techniques, such as the advent of nipple-sparing mastectomy, along with growing physician acceptance of new biomaterials capable of improving outcomes following implant-based breast reconstruction, are making mastectomy and reconstruction surgery a more attractive treatment option for many breast cancer patients and will help drive strong growth in the US breast reconstruction market in the years ahead.

You may also be interested in...



Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition

Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.

The Evolving World Of Breast Cancer Management

The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.

Hernia Repair: No Simple Solution

Hernia repair is a staple of the general surgeon’s practice, with more than two million procedures performed annually worldwide. However, the procedure has proven problematic due to the mesh products used to repair the hernia defect and their potential to cause complications over time. At the Fifth International Hernia Congress, held recently in New York City, physicians debated the pros and cons of the many hernia repair mesh products that are now available. Although the general consensus at the meeting was there is no “ideal mesh,” mesh manufacturers continue to innovate in this field, offering a host of new products for this $500+ million market, including a variety of biologic meshes for complex repairs, synthetic meshes with biologic-like properties, fully resorbable meshes, and meshes with bacteriostatic properties.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel